PGY-3 Internal Medicine @BCM_InternalMed
Houston, TX
Joined December 2025
- Tweets7
- Following54
- Followers22
- Likes11
Mitchell Boshkos retweeted
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!
Mitchell Boshkos retweeted
(1/4) Here's our clinical lab’s latest work led by @MitchellBoshkos, PGY-3, evaluating how cardiometabolic factors influence response to pre-operative ADT +/- ARPI in localized HRPCa in @pcan_journal
tinyurl.com/3u8r4vf9
Mitchell Boshkos retweeted
One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results
I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore
Mitchell Boshkos retweeted
(1/3) Here is our clinical lab’s latest work on how body composition influences the efficacy of nivo + ipi for pts with metastatic ccRCC shorturl.at/BKqhX in @jitcancer Led by @kgre23 @MourattJulia and collab with @PavlosMsaouel lab
Great few days at @ASCO GU in San Francisco.
Grateful to my mentor @OncHahn and the incredible GU team at @MDAndersonNews for the opportunity and support
#ASCOGU #ProstateCancer #GUOncology #MDAnderson
Great work by @MitchellBoshkos @kgre23 and @MourattJulia on their work investigating how cardiometabolic factors influence the efficacy of APM in men with localized and metastatic APMN prostate cancer #ASCOGU26 @BCM_InternalMed
Mitchell Boshkos retweeted
Great work by @MitchellBoshkos @kgre23 and @MourattJulia on their work investigating how cardiometabolic factors influence the efficacy of APM in men with localized and metastatic APMN prostate cancer #ASCOGU26 @BCM_InternalMed
